Rejoyn was developed by Otsuka and Click Therapeutics, a New York-based company that specializes in prescription software treatments.

The app is intended to reduce depression symptoms by having users identify and remember emotions displayed in a series of faces, which Otsuka claims can target neural connections needed to process emotions. 

Otsuka received 510(k) clearance for Rejoyn in March from the Food and Drug Administration. In a six-week, randomized, pivotal trial comparing Rejoyn to a sham app, patients who used Rejoyn saw a statistically significant improvement in the Montgomery-Åsberg Depression Rating Scale, a 10-item assessment widely used by clinicians to measure the severity of depression. 

After a patient is prescribed the program, digital pharmacy BlinkRx sends them a code to download Rejoyn from an app store.